- All sections
- C - Chemistrymetallurgy
- C07D - Heterocyclic compounds
- C07D 265/10 - 1,3-OxazinesHydrogenated 1,3-oxazines not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with oxygen atoms directly attached to ring carbon atoms
Patent holdings for IPC class C07D 265/10
Total number of patents in this class: 61
10-year publication summary
|
4
|
4
|
1
|
2
|
3
|
0
|
2
|
1
|
1
|
1
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Vitae Pharmaceuticals, Inc. | 94 |
8 |
| Boehringer Ingelheim International GmbH | 4636 |
5 |
| Instituto Mexicano Del Petroleo | 223 |
4 |
| Mirati Therapeutics, Inc. | 272 |
4 |
| Wisconsin Alumni Research Foundation | 3894 |
3 |
| Abbvie Inc. | 1817 |
3 |
| Gilead Calistoga LLC | 35 |
3 |
| Pfizer Inc. | 3401 |
2 |
| Merck Patent GmbH | 5752 |
2 |
| Nissan Chemical Industries, Ltd. | 1697 |
2 |
| NOVUS International, Inc. | 149 |
2 |
| The United States of America, as represented by the Secretary, Department of Health and Human Services | 2915 |
2 |
| Calico Life Sciences LLC | 104 |
2 |
| BASF SE | 21098 |
1 |
| The Regents of the University of California | 20303 |
1 |
| International Business Machines Corporation | 61747 |
1 |
| FUJIFILM Corporation | 29839 |
1 |
| Massachusetts Institute of Technology | 10150 |
1 |
| Agios Pharmaceuticals, Inc | 217 |
1 |
| Gilead Sciences, Inc. | 2106 |
1 |
| Other owners | 12 |